Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine
- Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine.
- In May 2020 Mymetics and Baylor College of Medicine in Texas signed a Research Agreement to preclinically produce and test virosomes incorporating SARS-CoV-2 recombinant proteins.
- As part of the Research Agreement, Mymetics has successfully produced several virosome vaccine formulations that will now be tested in a preclinical model at Baylor College of Medicine.